Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
NCT00236041
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Breakthrough Pain
Interventions
DRUG:
ACTIQ®
Sponsor
Cephalon